daunorubicin / Generic mfg. - LARVOL DELTA

Update AML: Updated disease monitoring and treatment to enhance outcomes for pediatric AML (NCT07059975) (ASH 2025) - P1 | "These patients will receive the common salvage regimen Idarubicin-fludarabine-cytarabine (IdaFLA) as the second cycle (Induction 2) in lieu of standard DA8 (Daunorubicin-Cytarabine) chemotherapy...In UPDATE AML, IR patients will receive VIA in place of MA (mitoxantrone-cytarabine) to eliminate exposure to the cardiotoxic agent mitoxantrone. HR patients will receive VIA as Intensification 1 prior to SCT, in place of the genotoxic agent etoposide and to provide venetoclax exposure prior to SCT...All newly diagnosed patients at TXCH >1 month to <30 years old with non-FLT3-ITD+ AML will be eligible for enrollment after completing standard Induction 1 chemotherapy consisting of combination of daunorubicin and cytarabine +/- gemtuzumab...Over 3 years, the study is anticipated to accrue 36-40 patients and generate important feasibility data for our treatment and molecular MRD innovations. Our results will inform future cooperative group trials with respect to..."

Clinical • IO biomarker • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Pediatrics • FLT3

Inhibitors of RAD51 as potential novel therapies in Acute Myeloid Leukemia (ASH 2025) - "Furthermore, these compounds often exhibit strong synergy and at least additivity in combination with both on-label and off-label use of FDA-approved compounds, as well as investigational molecularly-targeted agents, in relevant cell lines; these include FLT3 inhibitors quizartinib, gilteritinib and tuspetinib ((in MV-4-11 and HL60 cell lines) and BCR/ABL inhibitors (imatinib and regorafenib) in the K562 cell line (AACR 2025)...We have confirmed the IBRs inhibit multiple RAD51 functions including hydroxyurea-induced RAD51 focus formation, HRR by DR-GFP assay, and RS protection by RPA focus formation and a DNA fibre assay...JKYN-1 is a partially optimized (more soluble and more potent) version of IBR120 but is not resistant to degradation by liver microsomes or sufficiently capable of entry into target cells...Treatment dose and combinations will be pre-screened using a highly predictive cell line as a surrogate of human cancer stem cells for subsequently AML patient..."

Acute Myelogenous Leukemia • Colorectal Cancer • Hematological Malignancies • Leukemia • Solid Tumor • BRCA1 • BRCA2 • FLT3 • HRD • RAD51

Chronic myeloid leukemia and ASXL1 mutations: A distinct entity requiring special attention (ASH 2025) - "Initial treatment: nilotinib 800 mg/day, reduced to 200 mg BID due to hematologic toxicity...Started 7+3 (cytarabine + daunorubicin) + ponatinib on 05/20/2025...NGS:WT1 p.C29_L30insCRHPGPEPRSVC* VAF 1.39%, ASXL1 p.G645Vfs*58 VAF 1.55%, ASXL1 p.E929G VAF 1.46% ,ASXL1 p.T936= VAF 1.41%(Tier 1) Started R-HyperCVAD + dasatinib...In the current era of CML targeted therapy with TKIs or myristoyl inhibitors, the presence of associated genetic alterations (AGAs) becomes relevant, as they may predict aggressive behavior and open a window to evaluate transplantation in these patients for better therapeutic responses. Imatinib is not benefical in this patients."

Chronic Myeloid Leukemia • CNS Disorders • Hematological Disorders • Hematological Malignancies • Hepatology • Herpes Zoster • Infectious Disease • Leukemia • Liver Failure • Musculoskeletal Pain • Myeloproliferative Neoplasm • Respiratory Diseases • Varicella Zoster • ABL1 • ASXL1 • CD20 • CEBPA • GATA2 • WT1

A TFPI missense variant provides protection against severe febrile neutropenia in pediatric Acute Myeloid Leukemia (ASH 2025) - "Intensive chemotherapy regimens, such as the standard "7+3" induction protocol with cytarabine and daunorubicin, frequently result in severe neutropenia, markedly increasing susceptibility to infections (PMID: 38961525). Our study reveals a common genetic variant in CALCRL and TFPI to be associated with substantially reduced risk of severe FN during induction therapy in pediatric AML. Future directions include independent validation in larger and more diverse AML cohorts, and functional validation studies to uncover the mechanistic role of CALCRL and TFPI in observed toxicity. Ultimately, these insights could support the development of personalized supportive care strategies in pediatric AML."

Clinical • Acute Myelogenous Leukemia • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Neutropenia • Pediatrics • Septic Shock • ADM • CALCRL

Chidamide-based epigenetic therapy for relapsed/refractory Acute Myeloid Leukemia (ASH 2025) - P2 | "A total of 13 Asian Chinese subjects were enrolled in this study, including 9 males (69.2%) and 4 females (30.8%). The age range was 19 to 85 years old, with the youngest being 19 years old and the oldest being 85 years old, and the median age was 49 years old. 8 patients received chidamide combined with a hypomethylating agent (decitabine or azacitidine) plus daunorubicin and cytarabine or the HA regimen; the other 5 received chidamide combined with a hypomethylating agent (decitabine or azacitidine) and venetoclax."

Acute Myelogenous Leukemia • Gene Therapies • Hematological Malignancies • Leukemia

CHG combined with venetoclax and azacytidine as induction chemotherapy in acute myeloid leukemia (ASH 2025) - P2 | "Based on this premise, we endeavored to develop a low-dose, long-course CHG regimen (cytarabine, homoharringtonine, and granulocyte stimulating factor) in combination with the demethylating agent azacytidine and the Bcl-2 inhibitor venetoclax as an induction regimen(NCT06470841)...One patient achieved CRi after receiving daunorubicin plus cytarabine (DA) induction chemotherapy. However, the patient relapsed after completing 2 courses of consolidation chemotherapy (1 course of DA and 1 course of venetoclax + azacytidine + sorafenib)...In another patient, non-response (NR) was observed after 1 course of idarubicin plus cytarabine... In this trial, we utilized a low-dose, long-course regimen of CHG in combination with the demethylating drug azacytidine and the Bcl-2 inhibitor venetoclax as an induction regimen. Notably, all 5 patients achieved complete remission by a single course of VACHG induction chemotherapy, and the combined chemotherapy regimen demonstrated..."

Acute Kidney Injury • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Nephrology • Renal Disease

Myeloid sarcoma as a pancreatic cancer mimic: Refining the clinical differential of pancreatic masses (ASH 2025) - "The patient was initiated on hydroxyurea for initial leukoreduction. After receiving his bone marrow biopsy results with molecular characterization, he received induction therapy with gemtuzumab ozogamicin (3 mg/m 2 ) and a 7-day infusion of cytarabine (100 mg/m 2 /day) with 3 days of concurrent daunorubicin (60 mg/m 2 )...Adding IHC staining for CD43 and MPO can help reveal this diagnosis. Increased awareness and earlier diagnosis with intervention are critical to improved prognosis and reduced morbidity."

Clinical • IO biomarker • Acute Myelogenous Leukemia • Hematological Malignancies • Hepatology • Immunology • Leukemia • Oncology • Pancreatic Cancer • Pancreatitis • Sarcoma • Solid Tumor • CD20 • CD33 • CD34 • CD38 • CD79A • KIT • PTPRC • SDC1 • SPN

Acute Myeloid Leukemia: Diagnosis and treatment at a tertiary center in cochabamba - Bolivia. (ASH 2025) - "AML with PML::RARA fusion (acute promyelocytic leukemia, APL) has a better prognosis when treatment, based on trans retinoic acid (ATRA), plus arsenic trioxide (ATO) or chemotherapy is not delayed...Very few are commercially available but only daunorubicin, doxorubicin and cytarabine are provided by the public health insurance called, Seguro universal de Salud (SUS)...Shortness of ATRA availability is especially challenging. We need extensive report on cases from other hospitals throughout the country to better understand AML in Bolivia in order to improve patient care and insurance coverage in our country."

Acute Myelogenous Leukemia • Acute Promyelocytic Leukemia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Thrombocytopenia • CEBPA • NPM1

Favorable survival and tolerability of the GMALL protocol in adolescents and young adults with ALL: A single-center experience (ASH 2025) - "In general, pediatric and pediatric-inspired regimens involve high cumulative doses of vincristine, glucocorticoids, and asparaginase (ASP), with most regimens adding an anthracycline (usually doxorubicin or daunorubicin), along with intensive and prolonged central nervous system prophylaxis...Four patients (10%) were CD20 positive, and three of them received rituximab (3-7 doses in total). Five received blinatumomab prior to transplant for MRD eradication, and 16 underwent allogeneic transplantation in first complete remission (CR1)... Our single-center experience in AYA-ALL patients aged 18–40 treated with the pediatric- inspired GMALL protocol demonstrates favorable survival outcomes and good tolerability. These real-world findings align with previously reported GMALL clinical trial data and are comparable to outcomes seen with more intensive pediatric regimens in this age group."

Clinical • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Pancreatitis • CD20

T-lymphoblastic lymphoma presenting as pericardial tamponade: A rare initial manifestation of an aggressive malignancy (ASH 2025) - "The patient was initiated on induction chemotherapy (dexamethasone, daunorubicin, vincristine, peg-asparaginase) and discharged in stable condition. This case underscores the importance of including hematologic malignancies in the differential diagnosis of unexplained pericardial effusion and tamponade. Prompt imaging, cytology, and histopathologic confirmation are essential. Early Multidisciplinary coordination is critical to initiate timely and life-saving therapy in such rare and aggressive presentations."

Cough • Hematological Malignancies • Leukemia • Lymphoblastic Lymphoma • Lymphoma • Oncology • Pulmonary Disease • Respiratory Diseases • T Acute Lymphoblastic Leukemia • MME

Overall survival in patients with acute lymphoblastic leukemia in the aya population, treated with modified pediatric chemotherapeutic schemes, a real-life study (ASH 2025) - "Most patients received the LALÍN institutional regimen, which consists of 5 induction medications applied as follows: daunorubicin 120 mg / m2 for 48 hours on days 0 and 1, cyclophosphamide 1200 mg / m2 on day 2, vincristine 1.4 mg / m2 weekly for 4 weeks, prednisone 60 mg / m2 on day 2 to day 23. Philadelphia-positive patients were managed with dasatinib and negative patients with L-asparaginase 4,000 IU / m2, 3 times a week until consolidation, followed by intensification with cytarabine 1.5 g / m2 for 8 doses, consolidation with methotrexate 1 g / m2 and vincristine, and then early and subsequent maintenance...Therefore, our institutional regimen represents a good therapeutic option for patients in the AYA population, combined with immunotherapy management and transplantation in patients who relapse. key word: Acute lymphoblastic leukemia, adolescents and young adults, Overall survival"

Clinical • Acute Lymphocytic Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Obesity • Pediatrics • Thrombocytopenia

Azeliragon has significant activity against acute myeloid leukemia blasts (ASH 2025) - "Synergy analysis of OCI-AML3 cells with Combenefit software demonstrated high synergy scores when AZE was combined with cytarabine or venetoclax, medium synergy scores when combined with daunorubicin, and antagonism when combined with azacitidine...The relapse patients included 1 with relapse after 2 bone marrow transplants, 1 with relapse after 7 lines of treatment (including Revumenib), and another 1 with relapse after Revumenib...We conclude that AZE shows promising single agent activity in AML with potential for synergistic combinations with standard agents. Clinical investigation of AZE for the treatment of AML is warranted."

IO biomarker • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Alzheimer's Disease • Bone Marrow Transplantation • CNS Disorders • Hematological Malignancies • Leukemia • Solid Tumor • BCL2 • CD34 • HMGB1 • KMT2A

Filamin-a expression in Acute Myeloid Leukemia: A multi-omic analysis of prognostic, metabolic and therapeutic implications. (ASH 2025) - "In vitro FLNA knockdown was conducted in MLL-rearranged AML cell lines (MV4-11, MOLM-13) followed by assessment of drug sensitivity to Venetoclax, Cytarabine and Daunorubicin using cell viability assays...Pharmacotranscriptomic data from the BeatAML cohort revealed that FLNA expression correlates with ex vivo resistance to Venetoclax, Azacitidine, and Cytarabine... FLNA emerges as a multifaceted modulator of AML biology, associated with immune evasion, metabolic rewiring, chemoresistance, and poor prognosis. These findings position FLNA as a candidate biomarker and potential therapeutic target, warranting further investigation into its context-specific roles in AML pathogenesis and treatment resistance."

Omic analysis • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Solid Tumor • FLNA • IL6 • STAT3

From theory to therapy: Predicting response to chemotherapy with multiomic longitudinal profiling of peripheral blood in AML (ASH 2025) - "Afterdetection of overt AML (circulating cKit+ > 20%), CM mice (n=9) were treated with a "5+3" combination ofcytarabine (50mg/kg/day, 5 days) and daunorubicin (1.5mg/kg/day, 3 days), modeling the standard "7+3"chemotherapy...These miRNAs have not previously beenassociated with effects of standard-of-care chemotherapy in AML. The co-localization of these miRNAs toa region of the genome suggests a potential explanation for genome instability and chemotherapyresistance.In summary, this study provides a longitudinal multiomic characterization of genomic instability anddesynchronization of patterns of mRNA and miRNA expression induced by standard-of-care "7+3"therapy in AML, guided by mathematical analysis and critical points."

Acute Myelogenous Leukemia • Diabetes • Hematological Malignancies • Leukemia • Metabolic Disorders • Solid Tumor • Type 2 Diabetes Mellitus

Silibinin enhances daunorubicin chemosensitivity in Acute Myeloid Leukemia by suppressing PDIA3-mediated autophagy (ASH 2025) - "We measured autophagy flux using chloroquine (HCQ) and ATG5 siRNA. Silibinin,identified as an inhibitor of PDIA3, has been shown to restore autophagy and enhance chemosensitivityin both in vitro and in vivo models. This research highlights PDIA3 as a promising therapeutic target andpositions silibinin as a potentially effective chemosensitizer for the treatment of AML."

Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • ATG5 • CASP3 • GLI2 • PDIA3 • TINCR

Revumenib in combination with intensive induction and consolidation for newly diagnosed patients with NPM1-mutated or KMT2A-rearranged Acute Myeloid Leukemia: Preliminary results from the Phase 1b etctn 10596 study (ASH 2025) - P1 | "Revumenibwas combined with 7+3 induction (daunorubicin 60mg/m2 Days 1-3 and cytarabine 100mg/m2 Day 1-7)and cytarabine consolidation (1-1.5gm/m2 q12 hours (hrs) x 6 doses Days 1-3 based on age and CrCl).Revumenib dose escalation occurred independently between induction and consolidation on Days 2-28with dose level 1 (DL1) at 226mg q12hr and dose level 2 (DL2) at 276mg q12hr without strong CYP3A4inhibitor azoles. Revumenib combined with 7+3 overall appears to be well-tolerated both with 7+3 inductionand consolidation. However, the grade 5 typhlitis event in induction DL2 occurred on Day 7 of treatment,earlier than expected with 7+3, and thus was deemed possibly related to revumenib. As induction DL1has had no DLTs now in 6 patients, more data will be forthcoming on safety as additional patients havebeen enrolled on DL2."

Clinical • Combination therapy • P1 data • Acute Myelogenous Leukemia • Dermatology • Endocrine Disorders • Febrile Neutropenia • Neutropenia • FLT3 • KMT2A • NPM1

Bleximenib in combination with intensive chemotherapy: A phase 1b study in newly diagnosed Acute Myeloid Leukemia with KMT2A or NPM1 alterations (ASH 2025) - P1 | "We now report updated safety andefficacy data (clinical cut-off: July 2025) from this combination treatment in IC-eligible ND AML pts (CohortC1).MethodsIn the ALE1002 Phase 1b, multicenter, dose-finding study (NCT05453903), pts in Cohort C1 received astandard '7+3' regimen of cytarabine 200 mg/m2/day and daunorubicin 60 mg/m2/day intravenous (IV) oridarubicin 12 mg/m2/day IV in combination with bleximenib. Median duration of response was not reached. Four pts receiving bleximenib 100 mg BID incombination with '7+3' proceeded to allogenic transplant.ConclusionsIn ND NPM1m or KMT2Ar AML, the safety profile of bleximenib + '7+3', including count recovery, wasconsistent with a '7+3' IC backbone, with no DS adverse events and no QTc prolongation signal observed.Combined with early efficacy, the clinical data are supportive of a planned Phase 3 study of bleximenib +'7+3' in IC-eligible ND AML pts harboring KMT2Ar or NPM1m."

Combination therapy • P1 data • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Leukemia • Neutropenia • FLT3 • KMT2A • NPM1

Engineering dual-specificity PPM1D inhibitors to enhance therapeutic response and overcome chemoresistance in TP53-mutant malignancies (ASH 2025) - "We also performed multiplexed screens of morethan 700 cancer cell lines using daunorubicin with or without GSK2830371, as well as over 400 cancer celllines using vincristine with or without GSK2830371. Our data highlight new biological and medicinal chemistry strategies to engineer dualspecificity of PPM1D inhibitors, enhancing chemotherapeutic activity via PPM1D- and TP53-dependentand -independent mechanisms."

Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • ABCB1 • CDK1 • PPM1D • TP53

Blinatumomab following reduced-intensity induction chemotherapy in Chinese children with intermediate- or high-risk B-cell precursor acute lymphoblastic leukemia (ASH 2025) - P4 | "Eligibility criteria included: (1) intermediate-risk (MR) with MRD ≥1% bymultiparametric flow cytometry (MFC) at day 15; or (2) high-risk (HR) per the Chinese Children's LeukemiaGroup 2018-ALL (CCLG-2018-ALL) criteria at day 15.All patients received a reduced-intensity induction chemotherapy: daunorubicin (2 doses), vincristine (2doses), pegaspargase (1 dose), and prednisone about 2 weeks. ConclusionIn Chinese children with intermediate- or high-risk BCP-ALL, integrating blinatumomab after a reduced-intensity induction chemotherapy achieves high rates of deep molecular remission with a favorablesafety profile. These findings support the potential of immunotherapy-driven frontline strategies toimprove early outcomes and reduce long-term toxicity in pediatric BCP-ALL."

Clinical • IO biomarker • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Infectious Disease • Pancreatitis • Septic Shock • ABL1 • DUX4 • ETV6 • KMT2A • MEF2D • RUNX1

Quantitative ex vivo synergy profiling uncovers heterogeneous combination responses in AML primary samples (ASH 2025) - "Cells were seeded into 384-well plates and exposed to variousconcentrations of five drug pairs—two venetoclax (VEN)-based (VEN+decitabine, or VEN+azacitidine) andthree cytarabine (CYT)-based (CYT+daunorubicin, CYT+mitoxantrone, or CYT+idarubicin). In three patients, synergy was comparably high for both VEN- and CYT-basedpairs, whereas another three exhibited uniformly low synergy across all combinations. These findingsunderscore the potential of ex vivo synergy profiling to stratify AML patients for individualizedcombination therapy selection."

Heterogeneity • Preclinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • CD20

Mitoxantrone liposome plus cytarabine and azacitidine for newly diagnosed Acute Myeloid Leukemia: A prospective, multicenter, randomized controlled study (ASH 2025) - P3 | "daunorubicin or idarubicin, with the antimetabolitecytarabine—often known as the 7+3 regimen—which results in a complete remission (CR) rate of roughly60%. No treatment-related deaths were reported.Conclusion The MA+AZA regimen shows encouraging efficacy and manageable toxicity in newlydiagnosed AML. Preliminary efficacy was observed, with ongoing sample size expansion and follow-upextension to evaluate long-term survival outcomes"

Clinical • Acute Myelogenous Leukemia • Hematological Malignancies • Infectious Disease • Leukemia • Thrombocytopenia • CD34

Improved outcomes with higher cumulative doses of cytarabine consolidation in older patients with acute myeloid leukemia (ASH 2025) - "Most patients (86%) had de novo AML and all patients received induction with 7 days ofcytarabine and 3 days of anthracycline (idarubicin=53%, daunorubicin=47%). We report that cytarabine consolidation, either condensed or standard, is safe and feasible toadminister in older patients with no increased risk of neuro or nephrotoxicity and a high rate of allo-HSCT. A higher cumulative dose of cytarabine consolidation was associated with improved survivaloutcomes, compared to a lower dose. The choice of administering HIC vs."

Clinical • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia

A phase 2 clinical study on intensifying idarubicin dosage for inducing remission in acute myeloid leukemia patients aged 65 and younger (ASH 2025) - P1/2 | "Introduction: Until now, the standard induction therapy for acute myeloid leukemia (AML) has been acontinuous infusion of cytarabine at 100 to 200 mg/m² per day for 7 days, combined with eitheridarubicin at 12 mg/m² per day or daunorubicin at 45 to 90 mg/m² per day for 3 days. Intensifying the dose of idarubicin was effective and safe for remission induction therapy inadult AML patients. A phase 3 trial is warranted, and we propose an induction therapy regimen consistingof idarubicin at 18 mg/m² per day for 3 days alongside cytarabine at 100 mg/m² per day as a continuousinfusion for 7 days in adult AML patients without mutated FLT3. This trial was registered atwww.clinicaltrials.gov under #NCT01518556."

Clinical • P2 data • Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Mucositis • Neutropenia • Pneumonia • Respiratory Diseases • FLT3

Olutasidenib monotherapy in patients with mIDH1 Acute Myeloid Leukemia who received prior intensive chemotherapy (ASH 2025) - P1/2 | "This post hoc analysis evaluated the efficacy andsafety of olutasidenib monotherapy in a subset of patients (n=105) from the phase 2 pivotal cohort whohad received prior intensive chemotherapy (IC; e.g., high-dose cytarabine with daunorubicin,mitoxantrone with etoposide and cytarabine, or transplant conditioning regimens). The pivotal cohort of the global, multicenter, registrational, open-label phase 2 trial assessedolutasidenib 150 mg BID in adults with R/R AML harboring mIDH1. Among this cohort of patients with R/R mIDH1 AML who had received prior IC, treatmentwith olutasidenib monotherapy produced clinically meaningful response rates that closely align withthose observed in the overall population, with durable responses and acceptable tolerability. Thesefindings support the utility of olutasidenib in patients previously treated with intensive chemotherapy."

Clinical • Monotherapy • Acute Myelogenous Leukemia • Constipation • Febrile Neutropenia • Gastroenterology • Gastrointestinal Disorder • Hematological Malignancies • Leukemia • Neutropenia • IDH1

FLAG-IDA as frontline induction improves outcomes in pediatric patients with core-binding factor or KMT2A-rearranged acute myeloid leukemia: A multicenter cohort study in southern China (ASH 2025) - "Background : The FLAG-IDA (fludarabine, high-dose cytarabine, granulocyte colony-stimulating factor, andidarubicin) regimen is rarely used as frontline induction therapy for pediatric patients with de novo acutemyeloid leukemia (AML). Therefore, this study aimed to assess the efficacy and safety of FLAG-IDA forfrontline induction in pediatric patients with de novo AML and to analyze the treatment responses acrossvarious molecular subgroups. In this multicenter retrospective study, we evaluated the efficacy of FLAG-IDA (n=681; Group A)versus DAE (daunorubicin, Ara-C, and etoposide; n=194; Group B) induction as induction therapy,followed by two courses of consolidation therapy in 875 pediatric patients with de novo AML (2015–2023)in southern China... These findings indicate that frontline induction with FLAG-IDA, followed by two courses ofconsolidation, shortens chemotherapy duration, confers a significant survival advantage in pediatric CBF-AML, and achieves long-term..."

Clinical • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • Pediatrics • FLT3 • KMT2A • MLLT3